Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies.

about

Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies.

Item

http://www.wikidata.org/entity/Q54118869

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies.

@en

Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies.

@nl

type

Item

label

Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies.

@en

Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies.

@nl

prefLabel

Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies.

@en

Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies.

@nl

P1476

Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies.

@en

P2093

A F A S Teunisse

http://www.w3.org/2001/XMLSchema#string

A G Jochemsen

http://www.w3.org/2001/XMLSchema#string

M Nieveen

http://www.w3.org/2001/XMLSchema#string

R C Heijkants

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in GNA11 in uveal melanoma

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cdelta

Drug combination studies and their synergy quantification using the Chou-Talalay method

The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society.

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.

The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma

A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells.

Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.

P2888

s41389-018-0041-y

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41389-018-0041-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

K C 't Hart

P577

2018-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1101825777

http://www.w3.org/2001/XMLSchema#string

P698

29593251

http://www.w3.org/2001/XMLSchema#string

P932

5874255

http://www.w3.org/2001/XMLSchema#string